Please login to the form below

Not currently logged in
Email:
Password:

Shingrix

This page shows the latest Shingrix news and features for those working in and with pharma, biotech and healthcare.

GSK upbeat on its return to oncology market

GSK upbeat on its return to oncology market

Nevertheless, there is expected to be strong performances from its Shingrix vaccine and next-generation respiratory drug Ellipta, which have both been the focus of GSK’s new drive towards commercial

Latest news

More from news
Approximately 8 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    contain the adjuvant QS-21 Stimulon.  In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA.  GSK's malarial vaccine, Mosquirix which also contains

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics